A phase I open-label, non-randomized, dose-finding safety, tolerance and pharmacokinetic study of TSU-68 in combination with S-1 and oxaliplatin in patients with metastatic colorectal cancer.

Trial Profile

A phase I open-label, non-randomized, dose-finding safety, tolerance and pharmacokinetic study of TSU-68 in combination with S-1 and oxaliplatin in patients with metastatic colorectal cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2016

At a glance

  • Drugs Orantinib (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 03 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top